Nasrin Namdari
Overview
Explore the profile of Nasrin Namdari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shirzad-Yazdi N, Namdari N, Noorani A, Karimzadeh I
J Res Pharm Pract
. 2024 Nov;
13(1):27-32.
PMID: 39483994
Due to the high morbidity and mortality of the coronavirus disease 2019 (COVID-19) in patients with malignancy, the necessity of vaccination in this group of patients became particularly important. Although...
2.
Abedi A, Namdari N, Monabati A, Safaei A, Rajabi P, Mokhtari M
Int J Hematol Oncol Stem Cell Res
. 2023 Dec;
17(4):296-303.
PMID: 38076783
Myeloid sarcoma (MS) or chloroma is a localized mass composed of blastic cells of granulocytic lineage. It is a subtype of acute myeloid leukemia and usually presents as a complication...
3.
Dehghani M, Kashkooe A, Namdari N, Majidi R, Karimi M, Haghighat S, et al.
Expert Rev Hematol
. 2023 Jan;
16(4):289-295.
PMID: 36709461
Background: Hairy cell leukemia (HCL) is an indolent chronic lymphoproliferative disorder and first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Method: All 131 patients with...
4.
Iranpour P, Namdari N, Alavi M, Geramizadeh B
Curr Probl Cancer
. 2021 Jul;
46(1):100763.
PMID: 34247835
Background: Cystic angiomatosis is a rare benign disease presents with multiple lytic and sclerotic bone lesions mimicking a metastatic malignant neoplasia with less than 50 cases have been reported in...
5.
Ramzi M, Namdari N, Haghighat S, Haghighinejad H
Int J Hematol Oncol Stem Cell Res
. 2020 Oct;
14(3):171-176.
PMID: 33024523
Busulfan (BU) in combination with cyclophosphamide (CY) is used as an effective conditioning regimen in hematopoietic SCT. Busulfan, depletes glutathione level in liver and causes elevated levels of CY metabolites....
6.
Ramzi M, Haghighat S, Namdari N, Haghighinejad H
Exp Clin Transplant
. 2020 Aug;
19(12):1328-1333.
PMID: 32778017
Objectives: With the standard regimen for graft-versushost disease prophylaxis in allogeneic stem cell transplant with human leukocyte antigen-matched donor, grade II-IV acute graft-versus-host disease occurs in 30% to 50% of...
7.
Dehghani M, Jangjoo S, Monabati A, Masoomi Bandari D, Namdari N
Iran J Med Sci
. 2018 Dec;
43(6):659-663.
PMID: 30510343
The standard therapy for thyroid cancer is total or near total thyroidectomy, followed by the administration of radioactive iodine for remnant ablation or residual disease. Patients with radioiodine therapy are...